Physician profile
Julie Sage Weber Childers
NPI 1841654845
$803.64
in general payments reported to CMS, 2019-2025
13 companies · $180 in 2025
The $180 reported for 2025 was more than what 85% of Hospice and Palliative Medicine (Pediatrics) providers received nationally (typical 2025 total: $50.56).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $13.24 · 2021: $54.69 · 2022: $50.23 · 2023: $308 · 2024: $198 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $685.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $685.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corium, LLC | $243.65 | 2021-2024 | Azstarys |
| Ironshore Pharmaceuticals INC. | $148.24 | 2022-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $98.66 | 2024-2025 | Nucala, Bexsero, Penmenvy |
| Cranial Technologies, INC | $55.67 | 2020-2023 | Doc Band |
| Pfizer INC. | $49.44 | 2024 | |
| Tris Pharma INC | $49.02 | 2024-2025 | Dyanavel Xr, Onyda Xr |
| Sanofi-Aventis U.S. LLC | $32.98 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $32.30 | 2021 | |
| Noven Therapeutics, LLC | $23.93 | 2025 | Xelstrym |
| Merck Sharp & Dohme LLC | $23.35 | 2025 | Vaxelis, Gardasil 9, Enflonsia |
| Verrica Pharmaceuticals INC. | $17.71 | 2024 | Ycanth |
| Biomarin Pharmaceutical INC. | $14.98 | 2024 | Voxzogo 1.2mg |
| Vertical Pharmaceuticals, LLC | $13.71 | 2024 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julie Childers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.